Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Specified Nonprofit Corporation North East Japan Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with non-small cell lung cancer based on histological or cytological examination. 2. Among patients who received durvalumab as consolidation therapy following chemoradiotherapy, those who either: completed 1 year of durvalumab treatment,or discontinued consolidation therapy for reasons other than disease progression. 3. Patients who, between August 1, 2018 and March 31, 2023, received a platinum-doublet regimen as first-line therapy after recurrence at participating research institutions. The use of immune checkpoint inhibitors [PD-1 inhibitors / PD-L1 inhibitors with or without CTLA-4 inhibitors], anti-VEGF agents, or anti-EGFR monoclonal antibodies in combination is permitted.Patients who underwent prior local treatment for metastatic lesions [e.g., brain or bone metastases] before first-line therapy after recurrence may also be included.
Exclusion criteria
Exclusion criteria: 1. Patients positive for EGFR, ALK, ROS1, or RET gene mutations. 2. Patients who showed disease progression on the first systemic evaluation performed after completion or discontinuation of durvalumab consolidation therapy. 3. Patients who have expressed a refusal to participate in this study. 4. Patients deemed unsuitable for participation in this study by the principal investigator or sub-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Objective response rate, Adverse events | — |
Countries
Japan
Contacts
Public ContactHirokazu Iso
The Cancer Institute Hospital of JFCR Department of Thoracic Medical Oncology
Outcome results
None listed